Humanized and affinity matured antibodies to FcRH5 and methods of use
US11192950B2 · kind B2 · utility
0Cited by
52References
38Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 25, 2019 |
| Grant date | Dec 7, 2021 |
| Priority date | — |
| Expiry date | Mar 6, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to anti-FcRH5 antibodies, including anti-FcRH5 antibodies comprising an FcRH5 binding domain and a CD3 binding domain (e.g., FcRH5 T cell-dependent bispecific (TDB) antibodies), and methods of using the same.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.